Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Carmignac Gestion

Carmignac Gestion increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 182,507 shares of the biopharmaceutical company’s stock after acquiring an additional 65,936 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.5% of Carmignac Gestion’s portfolio, making the stock its 18th biggest holding. Carmignac Gestion owned 0.18% of Regeneron Pharmaceuticals worth $113,827,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth about $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $3,183,000. Gabelli Funds LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after acquiring an additional 5,120 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Harbor Mid Cap Value Fund’s Q2 2026 investor letter reportedly discusses the bullish potential of Regeneron, providing some support for the long-term investment case. Evaluating Bullish Potential in Regeneron Pharmaceuticals Stock
• Neutral Sentiment: Regeneron shares had gained about 8.1% over six months but lagged the S&P 500’s 13.6% return, prompting debate over whether the stock’s valuation and growth outlook remain attractive. Three Reasons to Avoid REGN
• Negative Sentiment: Pomerantz, Faruqi & Faruqi, Bernstein Liebhard, Robbins Geller, SBS Law and other firms are soliciting investors who purchased REGN shares between August 1, 2025, and May 15, 2026. Investors have until September 14, 2026, to seek appointment as lead plaintiff, increasing near-term legal overhang and investor attention. Pomerantz Investor Alert
• Negative Sentiment: The lawsuit follows what plaintiffs describe as surprising disclosures about the Phase III Fianlimab-Libtayo melanoma study. Investor notices allege that Regeneron’s statements about the trial were misleading before the shares declined from their class-period high. REGN Class-Action Deadline Alert

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on REGN shares. Citigroup lifted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Canaccord Genuity Group decreased their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $800.36.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock valued at $3,432,488 in the last 90 days. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.1%

Shares of REGN stock traded down $17.41 on Tuesday, hitting $810.31. The stock had a trading volume of 556,467 shares, compared to its average volume of 836,365. The company’s 50 day moving average price is $745.94 and its 200-day moving average price is $719.88. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $83.43 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.62 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $12.81 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.